Characterization of a Novel Cationic Drug Transporter in Human Retinal Pigment Epithelial Cells
Overview
Authors
Affiliations
Retinal pigment epithelial (RPE) cells transport a variety of solutes, but the capacity of human RPE cells to transport drugs and xenobiotics is not well understood. As an initial step to address this issue, we have examined human RPE transport of verapamil. Transport of [3H]verapamil was measured in two human RPE cell lines (RPE/Hu and ARPE-19) grown to confluence on 12-well culture plates. Verapamil uptake by RPE/Hu cells was highly concentrative, reaching cell-to-medium ratios as high as 42 by 1 h. Uptake was saturable, with an apparent K(m) of 7.2 microM. Verapamil uptake decreased in the presence of metabolic inhibitors, low temperature, and organic cations, including quinidine, pyrilamine, quinacrine, and diphenhydramine. However, other organic cations, including tetraethylammonium and cimetidine failed to inhibit. Verapamil uptake was also inhibited by the cationic antiglaucoma drugs diltiazem, timolol, and propranolol. Verapamil uptake was insensitive to changes in membrane potential. However, transport was markedly altered by changes in pH. Decreasing external pH inhibited uptake, whereas efflux was stimulated. Intracellular acidification via NH4Cl prepulse also stimulated uptake. Identical findings were obtained using the commercially available cell line ARPE-19. In view of its unique specificity, the RPE cell verapamil transporter described above is a novel, heretofore undescribed, organic cation transporter, distinct from the known members of the OCT family of organic cation transporters.
HIF2α activation and mitochondrial deficit due to iron chelation cause retinal atrophy.
Kong Y, Liu P, Li Y, Nolan N, Quinn P, Hsu C EMBO Mol Med. 2023; 15(2):e16525.
PMID: 36645044 PMC: 9906391. DOI: 10.15252/emmm.202216525.
Shinozaki Y, Akanuma S, Mori Y, Kubo Y, Hosoya K Pharmaceutics. 2021; 13(9).
PMID: 34575415 PMC: 8469395. DOI: 10.3390/pharmaceutics13091339.
Role of In Vitro Models for Development of Ophthalmic Delivery Systems.
Kutlehria S, Sachdeva M Crit Rev Ther Drug Carrier Syst. 2021; 38(3):1-31.
PMID: 34348017 PMC: 8694856. DOI: 10.1615/CritRevTherDrugCarrierSyst.2021035222.
Abruzzo T, Abraham K, Karani K, Geller J, Vadivelu S, Racadio J AJNR Am J Neuroradiol. 2020; 42(2):354-361.
PMID: 33361377 PMC: 7872184. DOI: 10.3174/ajnr.A6905.
Kubo Y, Yamada M, Konakawa S, Akanuma S, Hosoya K Pharmaceutics. 2020; 12(8).
PMID: 32784408 PMC: 7464812. DOI: 10.3390/pharmaceutics12080747.